Phase I study of KA2507, a selective HDAC6 inhibitor, in patients with relapsed or refractory solid tumors

Phase I study of KA2507, a selective HDAC6 inhibitor, in patients with relapsed or refractory solid tumors.
Tsimberidou A.M., Beer P., Bendall J., Dow J., King J., McElwaine-Johnn H. and Wistuba I.I.
Abstract CT151. American Association for Cancer Research Virtual Annual Meeting I; April 27-28 2020.